Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted antibody therapies for cancer. Its lead candidate, sirexatamab (DKN-01), inhibits DKK1 to treat various cancers, including colorectal and gastric cancers. The company leverages biomarker-driven approaches, immune modulation, and proprietary technology to create therapies aimed at improving patient outcomes in oncology markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.